This phase III trial is trying to determine whether a new targeted cancer drug (selpercatinib) can safely and effectively delay non-small cell lung cancers from returning in non-small cell lung cancer patients who have already received surgery or radiation.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Commercial Sponsor
Loxo Oncology, Inc.
Summary
Eligible participants will be randomised to receive oral selpercatinib or a placebo. Participants assigned to receive a placebo will have the option to crossover to selpercatinib if their disease comes back or gets worse. Participation could last for up to three years.
Recruiting Hospitals Read More